Allergic disorders and the risk of childhood acute lymphoblastic leukemia (United States)

Wanqing Wen¹, Xiao Ou Shu^{1,*}, Martha S. Linet², Joseph P. Neglia³, John D. Potter⁴,

Michael E. Trigg⁵ & Leslie L. Robison³

¹University of South Carolina, Columbia, SC, USA; ²National Cancer Institute, Bethesda, MD, USA; ³University of Minnesota, Minneapolis, MN, USA; ⁴Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ⁵A. I. DuPont Hospital for Children in Wilmington, DE, USA (*Author for correspondence)

Received 27 May 1999; accepted in revised form 28 September 1999

Key words: allergy, leukemia, sibling.

Abstract

Objectives: To test the hypothesis that childhood acute lymphoblastic leukemia (ALL) is associated with allergic disorders.

Methods: We compared the histories of selected allergic disorders (asthma, hay fever, food or drug allergies, eczema, and hives) of 1842 cases of ALL with those of 1986 individually matched controls. The histories of the allergic disorders among siblings of cases and controls were also compared.

Results: The combined history of any one or more of the five allergic disorders evaluated was associated with a significant reduced risk of ALL (adjusted OR = 0.7, 95% CI 0.6–0.8), as were histories of four specific allergic disorders (asthma, hay fever, food or drug allergies, and eczema). The combined history of any one or more of the five allergic disorders among any of the siblings of the study subjects also revealed a significantly inverse association (adjusted OR = 0.9, 95% CI 0.8–1.0).

Conclusion: The results from this study, in agreement with most previous studies on adult cancer, suggest that allergic disorders may be associated with a reduced risk of childhood ALL.

Introduction

Two contradictory hypotheses have been proposed concerning the relationship between allergic disorders and cancers, including leukemia. The immune surveillance hypothesis, postulated by Thomas and Burnet [1, 2], suggests that allergic disorders are protective against the occurrence of cancers because an enhanced immune system can detect and destroy malignant mutant cells [3]. Most epidemiologic evidence accumulated in the past 40 years seems to support this "hyperimmune" theory of allergic response [3–10]. Alternatively, it has been suggested that immune-stimulating conditions (including infectious diseases, allergies, and autoimmune diseases) increase the risk of cancers through a mechanism of chronic stimulation of cells that results in the occurrence of random mutations in actively dividing stem cells. This antigenic stimulation hypothesis has also been supported by some epidemiologic studies [11–13].

The complexity and heterogeneity of the association between various allergic disorders and various cancers may be one of the reasons that there are data supporting the different hypotheses [14]. To our knowledge, the relation between childhood acute lymphoblastic leukemia (ALL) and allergic disorders has not been studied. In an effort to improve our understanding of the association between selected common allergic disorders in children and childhood ALL, we present here the first epidemiologic evidence on the association, using the data obtained from interviews of subjects' mothers that were collected in a large-scale case–control study.

Correspondence to: Xiao Ou Shu, MD, PhD, Children's Cancer Group, PO Box 60012, Arcadia, CA 91066-6012, USA; Ph. (626) 447-0064 (ext. 122); Fax (626) 445-4334.

304

Materials and methods

Details of this case-control study have been described elsewhere [15]. Briefly, cases were identified through the member institutions of the Children's Cancer Group (CCG) throughout the United States [16]. Cases were newly diagnosed with ALL between 1 January 1989 and 15 June 1993, were under the age of 15 at diagnosis, and lived in a home with a telephone. Controls were randomly selected using a random digit dialing methodology previously described [17] and individually matched to cases on age (within 25% of age at diagnosis of the case, with a maximum difference of ± 2 years), race (white, black, or other), and telephone area code and exchange. In a few situations where an exact match could not be achieved after dialing 300 random numbers, relaxation of the age- and race-match was implemented. The control to case ratio was generally 1:1, except for the rare T-cell ALL subgroup, where more than one control was matched to each case. Additional eligibility criteria included the availability of an Englishspeaking biological mother for an interview.

A standard panel of monoclonal antibodies was applied to all diagnostic bone marrow specimens to determine B- or T-lineage. A subset of B-lineage leukemias was further classified by the determination of cytoplasmic immunoglobulin. Cases were assigned to one of the following mutually exclusive groups: T-cell ALL, early pre-B ALL (B-lineage markers positive, cytoplasmic immunoglobulin negative), pre-B ALL (Blineage markers positive, cytoplasmic immunoglobulin positive), B-lineage ALL-not otherwise specified (Blineage markers positive, but cytoplasmic immunoglobulin not performed), or unclassifiable.

During the study period, 2081 eligible cases and 2597 eligible controls were identified and a telephone interview was completed for 1914 cases (92.0%) and 1987 controls (76.5%). The 167 non-participating cases included 41 (2.0%) physician refusals, 70 (3.4%) parental refusals, 18 (0.9%) lost to follow-up, and 38 (1.8%) for miscellaneous reasons. Reasons for non-participation of 610 controls were 457 (17.6%) parental refusals, 17 (0.7%) lost to follow-up, and 136 (5.2%) for miscellaneous reasons. Matched controls or case were not found for 72 out of 1914 interviewed cases or 1 out of 1987 interviewed controls, respectively, resulting in 1842 case–control sets (1842 cases, 1986 controls, 1704 sets of 1:1 match, 132 sets of 1:2 match, and 6 sets of 1:3 match).

Information regarding the subjects' and their mothers' health history, details of maternal pregnancy and birth history, childhood diseases including allergic disorders of subjects and their siblings, family medical history, and parental occupational history was collected through a telephone interview of mothers of study subjects using structured questionnaires. Included in the current analysis were data on allergic disorders of the subjects and their siblings and data on potential confounding factors.

Conditional logistic regression models were used in data analyses to obtain odds ratios (OR) and their 95% confidence intervals (CI). Crude odds ratios were first estimated and then ORs were adjusted for potential

Table 1. Characteristics of cases and controls

(n) (n) Sex Male 1018 1076 1.0 Female 824 910 1.0 0.8–1.1 Race White 1492 1720 1.0 Other 350 266 2.6 1.9–3.5 Maternal education \leq High school 797 762 1.0 Some post-high 592 701 0.8 0.7–0.9 school 25 637 646 1.0 25-29 649 728 0.9 0.8–1.0 30–34 408 470 0.9 0.8–1.3 Income 520,000 607 546 1.0 \$20,000 507 546 1.0 \$25–0.6 0.5–0.8 Ever breastfed No 907 874 1.0 \$401 508 0.7 0.6–0.9 Maternal smoked during pregnancy No 1300 1429 1.0 Yes		Cases	Controls (n)	OR	95% CI
Sex Male 1018 1076 1.0 Female 824 910 1.0 0.8–1.1 Race White 1492 1720 1.0 Other 350 266 2.6 1.9–3.5 Maternal education \leq High school 797 762 1.0 Some post-high 592 701 0.8 0.7–0.9 school 2 25 637 646 1.0 25-29 649 728 0.9 0.8–1.0 30–34 408 470 0.9 0.8–1.3 Income < \$20,000 607 546 1.0 \$20,000 507 544 0.8 0.7–0.9 \$20,000 607 546 1.0 \$20,000 \$35 Ever breastfed No 907 874 1.0 \$6 60 noths 533 604 0.8 0.7–1.0 > 6 moths 401 508 0.7		(n)			
Male 1018 1076 1.0 Female 824 910 1.0 0.8–1.1 Race	Sev				
Female8249101.00.8–1.1RaceWhite149217201.0Other3502662.61.9–3.5Maternal education \leq High school7977621.0Some post-high5927010.80.7–0.9school \geq College4535230.80.7–0.9Maternal age (years) < 25 6376461.0 $25-29$ 6497280.90.8–1.0 $30-34$ 4084700.90.8–1.0 ≥ 35 1481421.00.8–1.3Income $<$ $<$ $<$ \leq S20,0006075461.0 $\leq 20,000$ 6075461.0 $\leq 20,000$ 4685960.6 $\geq 0.5-0.8$ Ever breastfed N_0 No9078741.0 ≤ 6 months5336040.8 ≥ 0.6 130014291.0 γ Yes5425571.1 No 130014291.0 γ Yes7688271.0 γ Yes7688271.0 $0-1$ 18710.2 $2-5$ 103055.9 $6-10$ 40922.2 $11+$ 21611.7ImmunophenotypeT-cell1839.9Early pre-B89348.5Pre-B23312.6B not specified23112.5Unknown30216.4 <td>Male</td> <td>1018</td> <td>1076</td> <td>1.0</td> <td></td>	Male	1018	1076	1.0	
Race White 1492 1720 1.0 Other 350 266 2.6 1.9–3.5 Maternal education \leq High school 797 762 1.0 Some post-high 592 701 0.8 0.7–0.9 school - - - - \geq College 453 523 0.8 0.7–0.9 Maternal age (years) - - - - < 25 637 646 1.0 - - $25-29$ 649 728 0.9 0.8–1.0 -	Female	824	910	1.0	0.8-1.1
Nate 1492 1720 1.0 Other 350 266 2.6 1.9–3.5 Maternal education \leq High school 797 762 1.0 Some post-high 592 701 0.8 0.7–0.9 school - - - - \geq College 453 523 0.8 0.7–0.9 Maternal age (years) - - - - < 25 637 646 1.0 - - $25-29$ 649 728 0.9 0.8–1.0 - <t< td=""><td>Race</td><td></td><td></td><td></td><td></td></t<>	Race				
Nume102110103Other3502662.6 $1.9-3.5$ Maternal education \leq High school797762 1.0 Some post-high592701 0.8 $0.7-0.9$ school \geq College453523 0.8 $0.7-0.9$ Maternal age (years) < 255 637 646 1.0 $25-29$ 649 728 0.9 $0.8-1.0$ $30-34$ 408 470 0.9 $0.8-1.3$ Income $< $20,000$ 607 546 1.0 \leq \$20,000 607 546 1.0 $\leq 20,000-S39,999$ 767 844 0.8 $0.7-0.9$ \geq \$40,000468596 0.6 $0.5-0.8$ Ever breastfed No 907 874 1.0 ≤ 6 months 533 604 0.8 $0.7-1.0$ ≥ 6 6 months 533 604 0.8 $0.7-1.0$ ≥ 6 6 months 401 508 0.7 $0.6-0.9$ Maternal smoked during pregnancy No 1300 1429 1.0 Yes 768 827 1.0 $0.9-1.2$ Maternal drank during pregnancy $\%$ $0-1$ 187 10.2 $2-5$ 1030 55.9 $6-10$ 409 22.2 $11+$ 216 11.7 11.7 Immunophenotype $T-cell$ 183 9.9 $Early pre-B$ 893 48.5 $Pre-B$ 233 12.6 <tr< td=""><td>White</td><td>1492</td><td>1720</td><td>1.0</td><td></td></tr<>	White	1492	1720	1.0	
Maternal education ≤ High school 797 762 1.0 Some post-high 592 701 0.8 0.7-0.9 school > 20 0.8 0.7-0.9 Maternal age (years) 25 637 646 1.0 25-29 649 728 0.9 0.8-1.0 30-34 408 470 0.9 0.8-1.3 Income	Other	350	266	2.6	1.9-3.5
Material education \leq High school7977621.0Some post-high5927010.80.7-0.9school \geq College4535230.80.7-0.9Maternal age (years) < 255 6376461.0 $25-29$ 6497280.90.8-1.0 $30-34$ 4084700.90.8-1.0 $\geqslant 35$ 1481421.00.8-1.3Income </td <td>Matamal advaction</td> <td></td> <td></td> <td></td> <td></td>	Matamal advaction				
Some post-high5927017021.0Some post-high5927010.80.7–0.9school \geq College4535230.80.7–0.9Maternal age (years)25–296497280.90.8–1.030–344084700.90.8–1.00.8–1.0 \geq 351481421.00.8–1.3Income\$20,0006075461.0\$20,000\$39,9997678440.80.7–0.9 \geq \$40,0004685960.60.5–0.8Ever breastfedNo9078741.0 \leq 6 months5336040.80.7–1.0> 6 months4015080.70.6–0.9Maternal smoked during pregnancyNo130014291.0Yes5425571.10.9–1.2Maternal drank during pregnancyNo107411591.0Yes7688271.00.9–1.2Age at diagnosis (years)%0–11.8710.22–5103055.96–1040922.211+21611.711.7ImmunophenotypeT-cell1839.9Early pre-B89348.5Pre-B23312.6B not specified23112.5Unknown30216.4	 High school 	707	762	1.0	
school 552 701 0.3 0.7-0.9 Maternal age (years) <	Some post high	592	702	0.8	0709
≥ College 453 523 0.8 0.7-0.9 Maternal age (years) < 25	school	592	/01	0.8	0.7-0.9
Maternal age (years) < 25 637 646 1.0 $25-29$ 649 728 0.9 $0.8-1.0$ $30-34$ 408 470 0.9 $0.8-1.3$ Income $1481421.00.8-1.3Standard Control520,0006075461.0$20,000-$39,9997678440.80.7-0.9\geqslant $40,0004685960.60.5-0.8Ever breastfedNo9078741.0\leqslant 6 months5336040.80.7-1.0> 6 months5336040.80.7-1.0> 6 months5336040.80.7-1.0> 6 months5336040.80.7-1.0Yes5425571.10.9-1.2Maternal smoked during pregnancyN_0130014291.0Yes7688271.00.9-1.2Age at diagnosis (years)\%\%0.70-118710.22.2.211+21611.7ImmunophenotypeT103055.96-1040922.211+21611.7ImmunophenotypeT12.6B not specified23112.5Unknown30216.4$	≥ College	453	523	0.8	0.7–0.9
< 256376461.025-296497280.90.8-1.0 $30-34$ 4084700.90.8-1.0 ≥ 35 1481421.00.8-1.3Income </td <td>Maternal age (years)</td> <td></td> <td></td> <td></td> <td></td>	Maternal age (years)				
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	< 25	637	646	1.0	
30-34 408 470 0.9 $0.8-1.0$ ≥ 351481421.0 $0.8-1.3$ Income $0.8-1.3$ $< $20,000 - $39,999$ 607 546 1.0 \$20,000 - \$39,999 767 844 0.8 $0.7-0.9$ ≥ \$40,000 468 596 0.6 $0.5-0.8$ Ever breastfedNo 907 874 1.0 ≤ 6 months 533 604 0.8 $0.7-1.0$ > 6 months 401 508 0.7 $0.6-0.9$ Maternal smoked during pregnancy No 1300 1429 1.0 Yes 542 557 1.1 $0.9-1.2$ Maternal drank during pregnancy No 1074 1159 1.0 Yes 768 827 1.0 $0.9-1.2$ Age at diagnosis (years) $%$ $0-1$ 187 10.2 $2-5$ 1030 55.9 $6-10$ 409 22.2 $11+$ 216 11.7 11.7 Immunophenotype $T-cell$ 183 9.9 Early pre-B 893 48.5 Pre-B 233 12.6 B not specified 231 12.5 Unknown 302 16.4	25–29	649	728	0.9	0.8 - 1.0
≥ 351481421.00.8–1.3Income< \$20,000	30-34	408	470	0.9	0.8 - 1.0
Income< \$20,000	≥ 35	148	142	1.0	0.8-1.3
Nome< \$20,000	Income				
\$20,000-\$39,999 767 844 0.8 0.7-0.9 ≥ \$40,000 468 596 0.6 0.5-0.8 Ever breastfed No 907 874 1.0 < 6 months	< \$20,000	607	546	1.0	
≥ \$40,000	\$20.000-\$39.999	767	844	0.8	0.7-0.9
Ever breastfedNo9078741.0 \leq 6 months5336040.80.7–1.0> 6 months4015080.70.6–0.9Maternal smoked during pregnancy No130014291.0Yes5425571.10.9–1.2Maternal drank during pregnancy No107411591.0Yes7688271.00.9–1.2Age at diagnosis (years)%0–118710.22–5103055.96–1040922.211 +21611.711.7ImmunophenotypeT-cell1839.9Early pre-B89348.5Pre-B23312.6B not specified23112.5Unknown30216.4	≥ \$40,000	468	596	0.6	0.5-0.8
No9078741.0 $\leq 6 \text{ months}$ 5336040.80.7–1.0> 6 months4015080.70.6–0.9Maternal smoked during pregnancy No130014291.0Yes5425571.10.9–1.2Maternal drank during pregnancy No107411591.0Yes7688271.00.9–1.2Age at diagnosis (years)%0–118710.22-5103055.96–1040922.211 +21611.711.7ImmunophenotypeT-cell1839.9Early pre-B89348.5Pre-B23312.6B not specified23112.5Unknown30216.4	Ever breastfed				
\leq 6 months5336040.80.7-1.0> 6 months4015080.70.6-0.9Maternal smoked during pregnancy No130014291.0Yes5425571.10.9-1.2Maternal drank during pregnancy No107411591.0Yes7688271.00.9-1.2Age at diagnosis (years)%0-118710.22-5103055.96-1040922.211 +21611.711.7ImmunophenotypeT-cell1839.9Early pre-B89348.5Pre-B23312.6B not specified23112.5Unknown30216.4	No	907	874	1.0	
> 6 months4015080.70.6–0.9Maternal smoked during pregnancy No130014291.0Yes5425571.10.9–1.2Maternal drank during pregnancy No107411591.0Yes7688271.00.9–1.2Age at diagnosis (years)%0–118710.22–5103055.96–1040922.211 +21611.711.7ImmunophenotypeT-cell1839.9Early pre-B89348.5Pre-B23312.6B not specified23112.5Unknown30216.4	≤ 6 months	533	604	0.8	0.7-1.0
Maternal smoked during pregnancy No130014291.0Yes5425571.1 $0.9-1.2$ Maternal drank during pregnancy No107411591.0Yes7688271.0 $0.9-1.2$ Age at diagnosis (years)% $0-1$ 18710.22-5103055.9 $6-10$ 40922.2 $11+$ 21611.7ImmunophenotypeT-cell183Pre-B23312.6B not specified23112.5Unknown30216.4	> 6 months	401	508	0.7	0.6-0.9
No130014291.0Yes5425571.1 $0.9-1.2$ Maternal drank during pregnancy No107411591.0Yes7688271.0 $0.9-1.2$ Age at diagnosis (years)%0 $0.9-1.2$ Age at diagnosis (years)%0 $0.9-1.2$ $0-1$ 18710.2 $2-5$ 103055.9 $6-10$ 40922.2 $11+$ 21611.7ImmunophenotypeT-cell183Tre-B23312.6B not specified23112.5Unknown30216.4	Maternal smoked du	tring pregnat	ncv		
Yes5425571.1 $0.9-1.2$ Maternal drank during pregnancy No107411591.0Yes7688271.0 $0.9-1.2$ Age at diagnosis (years)%00.9-1.2 $O-1$ 18710.22-5103055.96-1040922.211+21611.7ImmunophenotypeT-cell183Pre-B23312.6B not specified23112.5Unknown30216.4	No	1300	1429	1.0	
Maternal drank during pregnancy NoNo107411591.0Yes7688271.0 $0.9-1.2$ Age at diagnosis (years)%000-118710.22-5103055.96-1040922.211+21611.7ImmunophenotypeT-cell1839.9Early pre-B89348.5Pre-B23312.6B not specified23112.5Unknown30216.4	Yes	542	557	1.1	0.9-1.2
No 1074 1159 1.0 Yes 768 827 1.0 0.9–1.2 Age at diagnosis (years) % 0–1 187 10.2 2-5 1030 55.9 6–10 409 22.2 11+ 216 11.7 Immunophenotype T-cell 183 9.9 Early pre-B 893 48.5 Pre-B 233 12.6 B not specified 231 12.5 Unknown 302 16.4	Maternal drank duri	ng pregnanc	v		
Yes 768 827 1.0 0.9–1.2 Age at diagnosis (years) % 0-1 187 10.2 2-5 1030 55.9 6-10 409 22.2 11+ 216 11.7 Immunophenotype T-cell 183 Pre-B 233 12.6 B not specified 231 12.5 Unknown 302 16.4	No	1074	1159	1.0	
Age at diagnosis (years)% $0-1$ 18710.2 $2-5$ 103055.9 $6-10$ 40922.2 $11+$ 21611.7ImmunophenotypeT-cell183T-cell1839.9Early pre-B89348.5Pre-B23312.6B not specified23112.5Unknown30216.4	Yes	768	827	1.0	0.9-1.2
0-1 187 10.2 2-5 1030 55.9 6-10 409 22.2 11+ 216 11.7 Immunophenotype T-cell 183 9.9 Early pre-B 893 48.5 Pre-B 233 12.6 B not specified 231 12.5 Unknown 302 16.4	Age at diagnosis (ve	ars)		%	
2-5 1030 55.9 6-10 409 22.2 11 + 216 11.7 Immunophenotype T-cell 183 9.9 Early pre-B 893 48.5 Pre-B 233 12.6 B not specified 231 12.5 Unknown 302 16.4	0-1	187		10.2	
6-10 409 22.2 11 + 216 11.7 Immunophenotype T-cell 183 9.9 Early pre-B 893 48.5 Pre-B 233 12.6 B not specified 231 12.5 Unknown 302 16.4	2-5	1030		55.9	
11+ 216 11.7 Immunophenotype 11.7 T-cell 183 9.9 Early pre-B 893 48.5 Pre-B 233 12.6 B not specified 231 12.5 Unknown 302 16.4	6-10	409		22.2	
Immunophenotype T-cell 183 9.9 Early pre-B 893 48.5 Pre-B 233 12.6 B not specified 231 12.5 Unknown 302 16.4	11+	216		11.7	
T-cell 183 9.9 Early pre-B 893 48.5 Pre-B 233 12.6 B not specified 231 12.5 Unknown 302 16.4	Immunophenotype				
Early pre-B 893 48.5 Pre-B 233 12.6 B not specified 231 12.5 Unknown 302 16.4	T-cell	183		9.9	
Pre-B 233 12.6 B not specified 231 12.5 Unknown 302 16.4	Early pre-B	893		48.5	
B not specified 231 12.5 Unknown 302 16.4	Pre-B	233		12.6	
Unknown 302 16.4	B not specified	231		12.5	
	Unknown	302		16.4	

Allergy and childhood leukemia

confounders in multivariate models. Linear trend of the association was evaluated by treating the categorical variables as continuous in the models.

Results

As typical for ALL, cases were predominantly between the ages of 2 and 5 years (55.9%). Controls were more likely to be white, to come from a family with a higher maternal education level and family income, and to be breastfed more often than cases. These demographic characteristics, along with breastfed history, because of its potential relation with both ALL and allergic disorders, were controlled for their potential confounding effect. Subjects' sex, maternal age, maternal smoking and drinking during pregnancy were not significantly associated with the risk of ALL, nor did they significantly change allergy-associated odds ratios. We found no other major confounders (Table 1).

Allergic disorders included in this analysis were asthma, hay fever, food or drug allergies, eczema, and hives. As shown in Table 2, after adjusting for breast-feeding, maternal education, family income and race, the combined history of any one or more of the five allergic disorders evaluated was associated with a significant reduced risk of ALL (adjusted OR = 0.7, 95% CI 0.6–0.8), as were histories of four specific allergic disorders (asthma, hay fever, food or drug allergies, and eczema). History of hives was associated with a nonsignificant reduced risk for ALL. The risk of ALL decreased further if a child suffered two or more allergic disorders (trend p = 0.03). Reduced risk of ALL was observed for all age groups (Table 2), and for

Table 2. Allergic disorders of study subjects and childhood ALL, by age at diagnosis

Allergic disorders	Number of	Age at diagnosis (years)			
	attected subjects	0-1	2–5	6–10	11+
Asthma					
Case no.1	135	7	66	41	21
Ctrl no.1	176	10	89	49	28
OR (95% CI) ²	0.8 (0.6-1.0)	0.6 (0.2–1.7)	0.7 (0.5–1.1)	0.9 (0.5–1.4)	0.7 (0.3–1.3)
Hay fever					
Case no.	86	6	30	27	23
Crtl no.	150	5	60	52	33
OR (95% CI)	0.6 (0.5–0.8)	1.2 (0.3–4.7)	0.5 (0.3–0.9)	0.5 (0.3–0.8)	0.7 (0.4–1.4)
Food and drug allerg	ies				
Case no.	327	27	140	103	57
Crtl no.	487	40	226	133	88
OR (95% CI)	0.7 (0.6–0.8)	0.8 (0.4–1.4)	0.6 (0.5–0.8)	0.7 (0.5–1.0)	0.6 (0.4-0.9)
Eczema					
Case no.	91	2	58	19	12
Ctrl no.	145	13	79	37	16
OR (95% CI)	0.7 (0.5–0.9)	0.1 (0.0-0.6)	0.8 (0.6–1.2)	0.5 (0.3–1.0)	0.9 (0.4–2.3)
Hives					
Case no.	136	4	65	44	23
Ctrl no.	166	11	87	39	29
OR (95% CI)	0.9 (0.7–1.2)	0.3 (0.1–1.1)	0.9 (0.6–1.2)	1.3 (0.8–2.0)	0.8 (0.4–1.5)
Any above conditions	5				
Case no.	545	35	267	160	83
Ctrl no.	746	59	383	187	117
OR (95% CI)	0.7 (0.6–0.8)	0.6 (0.3–0.9)	0.7 (0.5–0.8)	0.9 (0.6–1.1)	0.6 (0.4-0.9)
No. suffered from any	y above disorders [OR (95%	% CI)]			
One condition	0.8 (0.7–0.9)	0.6 (0.4–1.1)	0.7 (0.6-0.9)	1.1 (0.8–1.5)	0.6 (0.4-1.0)
Two or more	0.6 (0.5-0.7)	0.4 (0.1–0.9)	0.6 (0.4-0.8)	0.6 (0.4–0.9)	0.6 (0.3-0.9)
Trend p	0.03	0.72	0.35	0.02	0.97

¹ Case no.: the number of cases with allergic disorder; Ctrl no.: the number of controls with allergic disorder.

 2 Odds ratios were adjusted for months of breastfeeding, maternal education, race, and family income. Tests for trend were assessed in logistic models containing a given factor as ordinal instead of as a set of indicator variables.

all immunophenotypes of the ALL cases (data not shown), although not all risk estimates were statistically significant.

In general, risk of ALL was reduced among children who had at least one sibling with one of the five specific allergic conditions. As presented in Table 3, the combined history of any one or more of the five allergic disorders among any of the siblings of the study subjects revealed a significant inverse association (adjusted OR = 0.9, 95% CI 0.8–1.0), although the OR estimate was significant only for specific history of hay fever (adjusted OR = 0.7, 95% CI 0.6–0.9) and food and drug allergies (adjusted OR = 0.8, 95% CI 0.7-1.0). Having three or more siblings affected might have the lowest risk of ALL (adjusted OR = 0.7, 95% CI 0.5-0.9), but no significant dose-response relationship was found (trend p = 0.44). All the analyses were adjusted for number of siblings, breastfeeding, maternal education, family income and race.

Discussion

The results from our study, in agreement with most previous studies on adult cancers [3-10], suggest that allergic disorders may be associated with a reduced risk of childhood ALL. Despite the current controversial status of the immune surveillance hypothesis, it has been observed that children with various congenital immunodeficiency diseases have an increased risk of developing lymphoid malignancies [18-20]. Abnormalities of the immune system are occasionally observed in patients newly diagnosed with ALL, but it is unclear whether these abnormalities precede the development of leukemia or are a consequence [18-20]. Our study cannot determine the time sequence of the relationship between allergic disorders and ALL because of the lack of information on the age at onset of allergic disorders. However, we found an inverse association between risk of ALL and eczema, an allergic disorder that usually occurs in infancy in our study, not only among infants but also among older children. This inverse association suggests that the less frequent allergic disorders in case children are unlikely to be a consequence of leukemia. In addition, we observed that some allergic disorders among the subjects' siblings, with whom the subjects may share genetic and environmental determinants of allergic disorders [21], were also associated with a reduced risk of ALL (Table 3). A 4-fold excess risk of childhood leukemia was estimated among siblings of ALL cases in one study [22]. Likewise, many serious allergic conditions have been determined to have a familial and genetic basis [21]. Thus, it is possible that an underlying familial or genetic basis may be responsible for

W. Wen et al.

Table 3. Allergic disorders among subjects' siblings and childhood ALL

Asthma Any sibling with 157 188 1.0 0.8–1.7 condition No. of siblings suffered	2
Any sibling with 157 188 1.0 0.8–1.7 condition No. of siblings suffered	2 2 2.1
condition No. of siblings suffered	2
NO. OI SIDIIIgs Suffered	1.2 2.1
1 135 167 0.9 0.7–1.	2.1
2+ 22 21 1.1 $0.6-2.$	
Trend p 0.58	
Hay fever	
Any sibling with 141 215 0.7 0.6–0.9).9
condition	
1 113 175 0.7 0.5-03	18
2+ 28 40 0.8 0.4-1.1	.3
Trend p 0.48	
Food and drug allergies	
Any sibling with 362 476 0.8 0.7–1.0	.0
condition	
No. of siblings suffered	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$).9 1
2+ 58 89 0.8 0.3-1. Trend <i>n</i> 0.40	.1
Fazama	
Any sibling with 114 141 0.9 0.7–1.	.2
condition	
No. of siblings suffered	
1 103 124 1.0 0.7–1.3	.3
2+ 11 17 0.8 0.4-1.7	.7
I rend p 0.23	
Hives	
Any sibling with 126 144 1.0 0.8–1.	2
No. of siblings suffered	
1 114 127 1.0 0.8–1.1	.3
2+ 12 17 0.7 0.3-1.	.6
Trend p 0.65	
Any above disorders	
Any sibling with 570 705 0.9 0.8–1.0	.0
condition	
No. of sublings suffered	1
$\begin{array}{cccccccccccccccccccccccccccccccccccc$.1
3+ 112 177 0 7 0 5-0 9	.ı).9
Trend <i>p</i> 0.44	

¹ Odds ratios were adjusted for the number of siblings, breastfeeding, maternal education, race, and family income.

the reduced risk of childhood ALL among children with certain types of allergic disorders. We conclude that our data support the immune surveillance hypothesis and suggest that the genetic and/or environmental factors that cause allergic disorders may also be protective against ALL. We hope that the finding reported here will

Allergy and childhood leukemia

stimulate more studies, including prospective surveillance studies of carefully defined allergic disease cohorts.

Acknowledgement

This work was supported by grant CA 13539 from the Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, to the Children's Cancer Group.

References

- Thomas L (1959) Reactions to homologous tissue antigens in relation to hypersensitivity. In: Lawrence HS, ed. *Cellular and Humoral Aspects of the Hypersensitive States*. New York: Hoeber-Harper, pp. 529–530.
- 2. Burnet FM (1957) Cancer a biological approach. IV. Practical application. *BMJ* 1: 844–847.
- 3. Severson RK, Davis S, Thomas DB, *et al.* (1989) Acute myelocytic leukemia and prior allergies. *J Clin Epidemiol* **42**: 995–1001.
- Vena JE, Bona JR, Byers TE, et al. (1985) Allergy-related diseases and cancer: an inverse association. Am J Epidemiol 122: 66–74.
- Linet MS, McCaffrey LD, Humphrey RL, et al. (1986) Chronic lymphocytic leukemia and acquired disorders affecting the immune system: a case-control study. J Natl Cancer Inst 77: 371–378.
- Cartwright RA, Darwin C, McKinney PA, *et al.* (1988) Acute myeloid leukemia in adults: a case–control study in Yorkshire. *Leukemia* 2: 687–690.
- La Vecchia C, D'Avanzo B, Negri E, *et al.* (1991) History of selected diseases and the risk of colorectal cancer. *Eur J Cancer* 27: 582–586.
- Bueno de Mesquita HB, Maisonneuve P, Moerman CJ, *et al.* (1992) Aspects of medical history and exocrine carcinoma of the pancreas: a population-based case-control study in the Netherlands. *Int J Cancer* 52: 17–23.

- Bernstein L, Ross RK (1992) Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case-control study in Los Angeles County. *Cancer Res* 52 (19 suppl.): 5510s–5515s.
- Dai Q, Zheng W, Ji BT, et al. (1997) Prior immunity-related medical conditions and oesophageal cancer risk: a populationbased case-control study in Shanghai. Eur J Cancer Prev 6: 152– 157.
- Gallagher RP, Spinelli JJ, Elwood JM, et al. (1983) Allergies and agricultural exposure as risk factors for multiple myeloma. Br J Cancer 48: 853–857.
- Bernard SM, Cartwright RA, Bird CC, et al. (1984) Aetiologic factors in lymphoid malignancies: a case–control epidemiological study. Leuk Res 8: 681–689.
- McWhorter WP (1988) Allergy and risk of cancer: a prospective study using NHANESI followup data. *Cancer* 62: 451–455.
- Mills PK, Beeson WL, Fraser GE, et al. (1992) Allergy and cancer: organ site-specific results from the Adventist health study. Am J Epidemiol 136: 287–295.
- Shu XO, Potter JD, Severson RK, *et al.* (1999) Diagnostic X-ray and risk of childhood acute lymphoblastic leukemia by immunophenotype. *Cancer* (In press).
- Robison LL, Buckley JD, Bunin G (1995) Assessment of environmental and genetic factors in the etiology of childhood cancers: the Childrens Cancer Group Epidemiology Program. *Environ Health Perspect* 103: 111–116.
- Robison LL, Daigle AE (1994) Control selection using random digit dialing for cases of childhood cancer. *Am J Epidemiol* 12: 164–166.
- Miller RW (1968) Relation between cancer and congenital defects: an epidemiologic evaluation. J Natl Cancer Inst 40: 1079–1085.
- Konior GS, Leventhal BG (1976) Immunocompetence and prognosis in acute leukemia. Semin Oncol 3: 283–288.
- Margolin JF, Poplack DG (1997) Acute lymphoblastic leukemia. In: Pizzo PA, Poplack DG, eds. *Principles and Practice of Pediatric Oncology*. Philadelphia, PA: Lippincott-Raven, pp. 409–448.
- 21. Huang SK, Marsh DG (1993) Genetics of allergy. *Ann Allergy* **70**: 347–360.
- Miller RW (1963) Down's syndrome (mongolism), other congenital malformations and cancers among sibs of leukemic children. *N Engl J Med* 268: 393–401.